Mike is a bioenergy and industrial biotechnology consultant and is an honorary Professor in Sustainable Bioenergy at the University of Nottingham. He is a council member for the BBSRC. Mike was previously with the Royal Dutch Shell Company for 21 years. He served as Global Manager for Shell's R&D Biofuels Programme in Shell’s Alternative Energies business. In this role, he led multi-disciplinary R&D teams in the Americas, Europe, and SE Asia, both within Shell, Universities, Institutes, and in partnerships with biotechnology startups such as Iogen, Codexis, Cellana, and Virent.
In his previous assignments, he was the Global Manager for Pervasive R&D Technologies, supporting Shell's Refinery operations, LNG, and Chemicals businesses. His team also provided trackside support for the Ferrari F1 team. Previous to this, he was responsible for the biochemical and molecular biology team at Sittingbourne Research Centre, UK involved in the molecular design of Agrochemicals.
Mike has a PhD in Biochemistry and was a Parkinson's Disease Research Fellow at the Medical School, Birmingham University, UK, before joining Dow Chemical Company where he worked for 6 years in the Agrochemical Business. Mike was made a Fellow of the Royal Society Of Chemistry in 2007.
With over 25 years of experience in the life sciences industry, Hilary is a Senior Director of Aequus Research and is based in London. Aequus Research provides highly effective market research to the healthcare industry, primarily the pharmaceutical sector. Hilary's focus is on providing strategic insights and guidance to companies in the development and commercialization of pharmaceutical products.
Hilary has a keen interest in research projects in particular evaluating novel technologies, targeted therapies, and in lifecycle management evaluations. Having worked with most of the top tier global pharma companies and many of the niche, specialist players, Hilary has a deep and rich network of contacts and specialists across the spectrum of the global pharmaceutical industry. She also continues to be an active contributor to international healthcare industry associations, including EphMRA.